药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Glembatumumab vedotin
The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Leronlimab
The risk or severity of adverse effects can be increased when Leronlimab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
CT-011
The risk or severity of adverse effects can be increased when CT-011 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
MYO-029
The risk or severity of adverse effects can be increased when MYO-029 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
RI 624
The risk or severity of adverse effects can be increased when RI 624 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
TNX-901
The risk or severity of adverse effects can be increased when TNX-901 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
PRO-542
The risk or severity of adverse effects can be increased when PRO-542 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ustekinumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Veltuzumab
The risk or severity of adverse effects can be increased when Veltuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Farletuzumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ramucirumab
The risk or severity of adverse effects can be increased when Ramucirumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Enokizumab
The risk or severity of adverse effects can be increased when Enokizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Iratumumab
The risk or severity of adverse effects can be increased when Iratumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
AMG 108
The risk or severity of adverse effects can be increased when AMG 108 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Otelixizumab
The risk or severity of adverse effects can be increased when Otelixizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Briakinumab
The risk or severity of adverse effects can be increased when Briakinumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
NAV 1800
The risk or severity of adverse effects can be increased when NAV 1800 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
XTL-001
The risk or severity of adverse effects can be increased when XTL-001 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Obiltoxaximab
The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Girentuximab
The risk or severity of adverse effects can be increased when Girentuximab is combined with Belantamab mafodotin.